On 10 December, two Innovative Medicines Initiative projects participated in an Alzheimer Europe Lunch Debate. The Lunch Debate was entitled “Improving the diagnosis of dementia – Findings from European research collaborations”.
Pierre Krolak-Salmon from the Institut du Vieillissement (Lyon, France) started with the first presentation. He introduced a consensus, developed as part of the Act on Dementia project. The speech focussed on a graduated diagnosis strategy tailored to the patients’ needs and wills. This strategy is based on a consensus that aims at clarifying appropriate components for primary and specialty care. The strategy has been published in a scientific journal and can be accessed here: https://www.ncbi.nlm.nih.gov/pubmed/31594224
Next, Mercè Boada from Fundació ACE (Coordinator of the Models of Patient Engagement for Alzheimer’s Disease project – MOPEAD) presented preliminary results. These included learnings on the effectiveness of the models of patient engagement that were tested and evaluated by the project.
After that, Gill Farrar from GE Healthcare held the closing presentation. Her speech revolved around the AMYPAD project. As part of this, she introduced its endeavours to clarify the role of brain imaging in the diagnosis and prognosis of Alzheimer’s disease.
Read more about the recommendations for policy makers and public education materials: https://www.mopead.eu/single-post/2019/12/12/MOPEAD-Policy-Recommendations-and-Public-Awareness-Strategy-now-available